KRAS and adenocarcinoma: Notably, we identified an exceptionally rare case involving four co-occurring KRAS mutations—G12D, G13D, Q61R, and A146T—in a 60-year-old male patient diagnosed with stage IVB adenocarcinoma (T4, N3, M1c).